Combination product to relieve the symptoms of sore throats

Abstract

The present invention relates to a combination product comprising, as active substances, at least honey, eucalyptus, and marshmallow root to help relieve the symptoms of sore throats. The invention also relates to the use of a combination product as defined above for the treatment of sore throats.

Description

Title of the invention: Combination product for relieving the symptoms of sore throats Technical field

[0001] The present invention relates to a combination product comprising, as active substances, at least honey, eucalyptus and marshmallow to help relieve the symptoms of sore throats. The invention finally relates to the use of a combination product as previously defined for the treatment of sore throats. Prior art

[0002] Sore throat is a common reason for consultation. It is a symptom rather than a disease in itself. It can be diffuse or localized to the tonsils, pharynx or larynx.

[0003] Locations of sore throat - pharyngitis: this is an inflammation of the tissues of the throat (pharynx). Swallowing, speaking or even breathing can become painful. - in tonsillar lesions (tonsillitis) the pain is more localized and located in one or both tonsils, and causes significant difficulty in swallowing. The pain can also radiate into the ear. - epiglottitis is an inflammation of the epiglottis (small cartilaginous tongue closing the larynx during swallowing). It is rare but potentially serious because it causes breathing difficulties

[0004] Sore throat is characterized by tingling, pain or burning sensations, and is sometimes associated with difficulty swallowing or speaking as well as other symptoms depending on the location and cause of the illness.

[0005] In 80% to 90% of cases, sore throat is caused by a virus. In 10 to 15% of cases, tonsillitis is due to a bacterial infection.

[0006] Sore throat of viral origin:

[0007] It may be pharyngitis or the beginning of viral rhinopharyngitis which is then followed by coughing, sneezing and nasal obstruction as in the flu for example.

[0008] Viral tonsillitis is usually accompanied by a moderate fever (between 38 and 39°). It can be caused by many common viruses, but also by mononucleosis or herpes, measles, chickenpox, etc.

[0009] Sore throat of bacterial origin:

[0010] Several types of bacteria can infect the throat.

[0011] Strep throat is caused by type A streptococcus (more rarely B or C). It is accompanied by fever, swelling of the tonsil, which may be red or dotted with white spots; in the neck, there is often a swollen and painful lymph node on the side of the affected tonsil. This tonsillitis can be serious when the streptococcus is group A because it can affect the entire body, particularly the kidneys and heart. It must therefore be treated quickly with antibiotics.

[0012] Tonsillitis:

[0013] Chronic tonsillitis is an inflammation of the tonsils that generally occurs after repeated tonsillitis, causing mild pain or discomfort when swallowing, but which may increase during periods of warming. The tonsillar "crypts" may fill with hard, whitish secretions, called caseum, which have a foul odor.

[0014] Epiglottitis: Epiglottitis is usually caused by the bacteria that causes pneumonia and meningitis, Haemophilus influenzae type B (Hib). This disease has become exceptional since the widespread use of vaccination against Haemophilus influenzae in children.

[0016] Sore throats can also be caused by: - An allergic reaction to animal hair, mold, or pollen. - Dry air, especially in winter when houses are heated or in summer due to air conditioning. - Pollution or chemical irritants such as tobacco smoke or evaporation from products such as glues, paints, household products, etc. - Pharyngolaryngeal inflammation after vocal overexertion. - Gastroesophageal reflux causing pharyngitis due to the rise of acidic liquid from the stomach into the throat. - A sore throat that persists for more than 1 week may be a sign of a more serious problem: - HIV infection, gonococcal infection. - The presence of a tumor of the pharynx or larynx.

[0017] Possible complications:

[0018] Most sore throats, although uncomfortable, will get better on their own within 5 to 7 days. A sore throat caused by bacteria can lead to certain complications.

[0019] To relieve sore throats, there are various products on the market. These products generally contain paracetamol, local anesthetics, such as lidocaine or tetracaine, corticosteroids, such as tixocortole, antibacterials, such as chlorhexidine, hexamidine, antiseptics such as biclotymol, benzalkonium, amylmetacresol, cetylpyridinium. Such products are marketed by Laboratoires URGO under the trade name HUMEX® sore throat biclotymol or HUMEX® sore throat lidocaine or HUMEX sore throat lidocaine / benzalkonium, or by Sanofi-Aventis under the trade name SOLUTRICINE MAUX DE GORGE TÉ-TRACAINE, or ANGISPRAY MAL DE GORGE CHLORHEXIDINE / LIDOCAINE by Laboratoires P&G Health. These compositions, due to the presence of active molecules such as paracetamol, lidocaine, tetracaine, tixocortole, chlorhexidine, hexamidine, biclotymol, benzalkonium, amylmetacresol or cetylpyridinium, have the disadvantage of not being able to be used by the entire population.Indeed, certain products should not be used by children under 12 years old or by pregnant or breastfeeding women and may have undesirable effects.

[0020] In addition, consumers are increasingly opting for natural solutions and are reluctant to use active ingredients such as those described above.

[0021] Among the existing natural solutions, we can cite as an example Lehning Swiss Paste Propolis and Honey, Oropolis Soothes the Throat Liquid Heart from Mediflor Laboratory based on propolis, Activox Mint Eucalyptus from Arkopharma based on erysimum and matricaria, Pranarom Aromaforce Honey Lemon Gums based on essential oils of Lemon, Eucalyptus globulus, Thyme, Mandarin and lemongrass.

[0022] None of the products proposed contain the combination which is the subject of the present invention.

[0023] The Applicant has developed, and this is the subject of the present invention, a product of combination comprising as active substances, at least honey, eucalyptus and marshmallow to help relieve the symptoms of sore throats.

[0024] Preferably, the honey of the combination product according to the invention is a Manuka honey.

[0025] By "relieving the symptoms of sore throats" is meant, in the context of the present invention, a product which makes it possible to soothe the throat, relieve tingling, pain or burning sensations, and alleviate difficulties in swallowing.

[0026] Such a product therefore makes it possible to relieve the symptoms of sore throats with products of natural origin and to treat a greater number of people.

[0027] The product according to the present invention also has the advantage of preferably containing no artificial coloring, allergens and of being, preferably, lactose-free or gluten-free.

[0028] The product of the present invention has a galenic suitable for adults and children over 6 years old, preferably in the form of a lozenge to suck.

[0029] The product according to the present invention, although containing products of natural origin, has a pleasant taste and smell.

[0030] The lozenge according to the invention advantageously has a solid shell and a melting core, the two textures being perceptible after sucking.

[0031] Preferably, the lozenge according to the invention has a very good honey taste, is soft and pleasant in the mouth when sucked.

[0032] Advantageously, the lozenge according to the invention does not stick to the fingers when it is taken in hand.

[0033] Once in the mouth, advantageously, the lozenge according to the invention does not stick to the tongue or the palate and the hard bark does not injure the palate.

[0034] The release of the melting heart provides a coating effect in the throat, thus helping to relieve the symptoms of sore throats, in particular by reducing pain when swallowing. Summary

[0035] The present invention relates to a combination product, comprising as active substances, at least honey, eucalyptus and marshmallow to help relieve the symptoms of sore throats.

[0036] The present invention also relates to a combination product, comprising as active substances, at least honey, eucalyptus, and marshmallow for use in the treatment of sore throats.

[0037] In certain embodiments, the combination product according to the invention comprises, in addition to honey, eucalyptus and marshmallow, as active substances: - Plants or plant extracts, such as poppy - Vitamins and minerals, such as vitamin C,

[0038] In certain embodiments, the combination product of the invention is characterized in that it is in the form of a single composition comprising at least: - (i) 50 to 500 mg, preferably 100 to 400 mg of honey - (ii) 1 to 10 mg, preferably 2 to 5 mg of eucalyptus, preferably E ucalyptus globulus - (iii) 5 to 200 mg, preferably 10 to 100 mg of marshmallow

[0039] Eucalyptus may be present as ingredient (ii) in a combination product of the invention in more or less purified form, in particular in the form of essential oil.

[0040] Marshmallow may be present as ingredient (iii) in a combination product of the invention in more or less purified form, in particular in the form of plant extract.

[0041] The honey is preferably Manuka honey.

[0042] According to a particular embodiment of the invention, the combination product is characterized in that the active ingredients (i), (ii) and (iii) are in a medium suitable for oral administration. Preferably, the suitable medium is a solid medium. Preferably, the combination product is in the form of a lozenge.

[0043] The various embodiments of the invention are particularly described in the detailed description below. These embodiments can be taken separately or in combination with each other. Description of the embodiments

[0044] In the present invention, the applicant has demonstrated that the combination of honey, eucalyptus and marshmallow has a synergistic effect to help relieve the symptoms of sore throats.

[0045] By synergistic effect, it is understood according to the present invention that the combination of honey, eucalyptus and marshmallow has an effect on the relief of the symptoms of sore throats, during the treatment which is greater than the cumulative effects of a treatment (a) comprising the administration of honey, not associated with eucalyptus and marshmallow, and conversely of a treatment (b) comprising the administration of eucalyptus, not associated with honey and marshmallow or of a treatment (c) comprising the administration of marshmallow not associated with honey and eucalyptus.

[0046] Honey

[0047] In the present invention, the expression "honey" must be understood in its broadest interpretation and as designating the sweet substance produced by honey bees, from the nectar of the flowers they forage: on the flower, the bee sucks up the nectar or "honeydew" and stores it in its crop. Loaded with this liquid, it returns to the hive and transmits it to another bee. This same liquid then passes from bee to bee, from mouth to mouth and from crop to crop. The last of the workers to intervene deposits the enriched nectar drop by drop in a cell. After a few days, when the honey is "ripe", that is to say when it has lost enough moisture, the bees close the cells with a wax cap.

[0048] Honey is essentially composed of a supersaturated solution of different sugars, the two main ones being glucose and fructose. Honey is also composed of 17% water, 79.5% carbohydrates and 3.5% other particles. These proportions can vary from one honey to another, from one type of culture to another or even from one country to another.

[0049] In the context of the present invention, the honey is preferably a Manuka honey.

[0050] Indeed, Manuka honey also contains specific antibacterial and antiseptic properties. The Manuka Honey Promotion Consortium (New Zealand) created the UMF (Unique Manuka Factor) in order to be able to measure these properties. This honey is effective against multi-resistant bacteria (enterococcus or Staphylococcus aureus, Streptococcus pyrogenes) and appears to have anti-inflammatory and healing properties.

[0051] While other honeys (Thyme, Sidr from Yemen) are known to have excellent antiseptic, antibacterial and healing properties, no scientific comparison of the qualities of these different honeys exists to date.

[0052] Methylglyoxal is the active compound in Manuka honey.

[0053] OMA, which stands for “Organic Manuka Active”, is sometimes used; it indicates the methylglyoxal content of honey in the same way as MGO or IAA.

[0054] In a preferred embodiment of the invention, the methylglyoxal content is IAA15+.

[0055] According to a preferred embodiment of the present invention, the honey is present in the composition according to the invention in a content of 50 to 500 mg, preferably 100 to 400 mg per single composition.

[0056] Eucalyptus

[0057] Native to Australia, the genus Eucalyptus has produced more than 600 species ranging from simple shrubs to very large trees. Several tree species have long been cultivated in the Mediterranean basin and in all subtropical regions, both in the East and the West.

[0058] European aromatherapy mainly uses the essential oil of four species of eucalyptus. - • Lemon eucalyptus (E. citriodora). Preferred for topical applications (arthritis, tendonitis, itching, mosquito repellent, etc.). - • Mentholated eucalyptus (E. dives). Preferred for respiratory tract conditions ratories, but the use of its essential oil is not recommended for children under 6 years old and for pregnant or breastfeeding women. - • Eucalyptus radiata (E. radiata\ Better tolerated by mucous membranes and skin; Suitable for children. Not recommended during the first three months of pregnancy. - • Multibracted Eucalyptus (E. polybracteaCT cryptone). Preferred for parasitic diseases (tropical diseases, in particular) and for gynecological or urinary infections of viral origin. The essential oil is not recommended for children under 6 years old and for pregnant or breastfeeding women.

[0059] Researchers believe that the medicinal properties of eucalyptus are mainly due to the eucalyptol (also called 1,8-cineole) contained in its leaves. This is why we generally agree that, to be effective, the essential oil must contain 70% to 85%

[0060] Recognized use: The European Commission has approved the use of the leaves (internal use) and essential oil (internal and external use) of Eucalyptus globulus, to treat inflammation of the respiratory tract.

[0061] The World Health Organization recognizes the traditional use of eucalyptus leaves (E. globulus) to relieve fever and symptoms of asthma, inflammation of the respiratory tract, bronchial tubes or throat.

[0062] Preferably, the Eucalyptus present in the combination product according to the invention is Eucalyptus globulus. This is present, preferably, in the form of essential oil.

[0063] According to a preferred embodiment of the present invention, eucalyptus is present in the composition according to the invention in a content of 1 to 10 mg, preferably 2 to 5 mg per single composition.

[0064] Marshmallow

[0065] Marshmallow (Althaea officinalis Lp also called Wild Marshmallow or White Mallow, is a perennial herbaceous plant of the Malvaceae family, common in Europe. It is cultivated as a medicinal plant for its emollient properties, as an ornamental plant for its flowers and sometimes as a vegetable plant mainly for its roots.

[0066] This plant, rich in mucilages, has softening, emollient, bechic, laxative and aperitif properties.

[0067] According to a preferred embodiment of the present invention, the marshmallow is present in the composition according to the invention in a content of 5 to 200 mg, preferably 10 to 100 mg per single composition.

[0068] Physiologically acceptable medium

[0069] A physiologically acceptable medium is a medium having no toxic or detrimental effects under the conditions of use and inert with respect to the active ingredients of the combination product. Such a medium may, for example, comprise different adjuvants depending on its therapeutic or cosmetic purpose, such as, but not limited to, flavorings, colorants, fillers, preservatives, diluents, wetting or suspending agents, etc. Such media may also allow immediate, modified or delayed release of one or other of the active ingredients.

[0070] The physiologically acceptable medium may be composed of texturizers, emulsifiers, colorants, preservatives, flavorings or sugar.

[0071] By "texturants" is meant compounds that modify the texture of the products in which they are incorporated. Examples of texturants are: guar and carob flours; gums arabic, xanthan, acacia and gellan; car- raghenans; starches (native or modified); microcrystalline cellulose; gelatin; pectin; alginates (E400 to E405); agar-agar; and mixtures thereof. By "emulsifiers" is meant amphiphilic compounds characterized by their HLB (Hydrophilic Lipophilic Balance) value, in particular capable of stabilizing oil-in-water emulsions (particularly interesting if one wishes to add, for example, fat-soluble active ingredients such as fat-soluble vitamins. Examples of food emulsifiers are lecithin and its derivatives present in particular in egg yolk; mono- and diglycerides of fatty acids; and polysorbate 80.

[0072] By "colorants" is meant compounds of natural or synthetic origin capable of conferring a coloring to the composition on their own. Examples of food colorings are known in Europe under the codes El00 to El80.

[0073] By "preservatives" is meant compounds inhibiting the proliferation of microorganisms, in particular yeasts and / or molds and / or bacteria, in particular Staphylococcus Aureus, in the composition. Examples of food preservatives are sorbic acid and its salts (E200 to E203); benzoic acid and its salts (E210 to E219); sulfites and derivatives (E220 to E228); natamycin; nisin; and mixtures thereof. Preferably, the composition according to the invention does not comprise any preservative.

[0074] By "flavors" is meant compounds of natural or synthetic origin capable of modifying the taste of the composition on their own. Examples of flavors are apricot, pineapple, banana, blackcurrant, cherry, lemon, lime, strawberry, raspberry, passion fruit, mandarin, mint, orange, pistachio, pear, licorice, rose, anise, blueberry, cinnamon, ginger, grapefruit, apple, kiwi, lychee, melon, coconut, peach, redcurrant, guava, grenadine, mango, blackberry, papaya, tea, vanillin, natural vanilla extract, essential oils and mixtures thereof.

[0075] For the purposes of the present invention, the term "sugar" or "sugars" or "sweetening agent" means any sweetening carbohydrate, preferably glucose syrup, sucrose, glucose, fructose, invert sugar, honey, maltose, polyol or mixtures thereof. In the context of the present invention, the sweetening agent used is glucose syrup combined with sucrose.

[0076] Additional asset(s)

[0077] Any additional active ingredient having nutritional value and / or helping to relieve the symptoms of sore throats may also be added to the combination products of the invention. The combination product may comprise, for example, vitamins, mineral salts, essential amino acids, essential fatty acids, trace elements, various plant extracts, fibers, antioxidants, flavonoids.

[0078] Advantageously, such an additional active ingredient may be intended to reinforce the desired effect as described above.

[0079] Of course, those skilled in the art will take care to choose the additional active ingredients and their quantity in such a way that the advantageous properties of the composition in accordance with the invention are not, or not substantially, altered by the envisaged addition.

[0080] As additional usable assets, we can cite: - - water-soluble vitamins and fat-soluble vitamins. Examples of Water-soluble vitamins present in the syrupy product prepared according to the invention include: vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (nicotinic acid) also called vitamin PP (Pellagra Preventive), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine), vitamin B8 or H (biotin), vitamin B9 (folic acid) and vitamin B12 (cobalamin). Examples of fat-soluble vitamins present in the syrupy product prepared according to the invention include: vitamin A (retinol), vitamin D3 (cholecalciferol), vitamin E (mixture of tocopherols and tocotrienols) and vitamin K (phylloquinone). - - antioxidants, such as curcuminoids; carotenoids, in particular chosen from beta-carotene, astaxanthin, zeaxanthin, lutein or compounds containing them such as goji berries; polyphenol compounds, flavonoids such as catechins; proanthocyanidins, anthocyanins, OPCs (procyanidolic oligomers); ubiquinones; coffee extracts containing polyphenols and / or diterpenes; chicory extracts; ginkgo biloba extracts; grape extracts rich in proanthocyanidins; chili pepper extracts; soybean extracts; cocoa; pomegranate; Emblica; Coenzyme Q10; selenium, - - minerals, such as magnesium, calcium, copper, iron, iodine, manganese, selenium, chromium (III), - - amino acids, especially sulfur-containing amino acids, such as pre glutathione sliders, selenium amino acids, citrulline, - -phytosterols, resveratrol, hesperidin, neohesperidin, ortho-silicic acid, monomethylsilanetriol, and mixtures thereof.

[0081] Preferably, a combination product according to the invention is administered orally. Forms suitable for oral administration are, for example, tablets, capsules, lozenges, gums, powders, granules, lyophilisates, oral solutions and syrups. Tablets, gums, powders, granules, lyophilisates, oral solutions and syrups constitute the currently preferred pharmaceutical form suitable for oral administration. In the case of the preparation of a composition solid in the form of tablets, for example, the main active ingredients (i), (ii) or (iii) can be mixed with a physiologically acceptable vehicle such as sucrose and / or glucose syrup.

[0082] Example 1: composition according to the invention (Table 1):

[0083] [Tables 1] Raw material Quantity per lozenge (in mg) Eucalyptus globulus essential oil 3.2 Althae officinalis root extract (P / E ratio = 4 / 1) 20.83 honey 370 sucrose 1480 glucose syrup 1430

[0084] This composition is obtained by mixing the different compounds according to the processes conventionally used for this type of preparation. The composition is in the form of a lozenge with a hard shell and a melting center. This lozenge will be taken, preferably, by subjects with sore throats throughout the day. The recommended dosage is 1 to 6 lozenges per 24 hours.

[0085] Example 2: Perception survey of the lozenge according to example 1 compared to the Oropolis “Liquid Heart” lozenge based on propolis from the Mediflor Laboratory.

[0086] 66 panelists evaluated the two lozenges one after the other, at the level of their performance. perceptions in the mouth (taste, coating effect, texture, etc.). They kept each lozenge in their mouth until it had completely melted and waited approximately 1 hour between the two tastings, this with the aim that all perceptions in the mouth of the first lozenge had disappeared.

[0087] The panelists were asked to rinse their mouths before each tasting.

[0088] The panelists were asked to take the lozenge in their hands and say whether they: Strongly disagree / Disagree / Moderately agree / Agree / Strongly agree that the lozenge did not stick to their fingers.

[0089] Overall, with 97% of “agree” and “completely agree” responses for the Oropolis lozenge and 74% for the lozenge according to example 1, the 2 lozenges do not stick to the fingers when you take them in your hand.

[0090] Once placed in the mouth, the melting heart lozenge according to example 1 and the Oropolis liquid heart lozenge do not stick, either to the tongue or to the palate (no significant difference between the 2 lozenges).

[0091] The panelists explained that the 2 lozenges are smooth and slide well in the mouth without sticking.

[0092] With averages ranging from approximately 7 to 8 out of 10, the panelists were satisfied with the taste of the 2 pastilles tasted.

[0093] With an average taste satisfaction score of 8.1 out of 10, the melting heart lozenge according to example 1 has a very appreciated taste. Its taste is significantly more satisfactory than the taste of the Oropolis lozenge which receives an average taste satisfaction score of 7.1 out of 10.

[0094] The panelists explained that they appreciated the pleasant and sweet taste of honey in the mouth when tasting the melting heart lozenge according to example 1. Some panelists detected a eucalyptus aroma, which they appreciated and which, for them, brought a note of freshness to the lozenge.

[0095] Regarding the Oropolis lozenge, the panelists explained that its taste is satisfactory before the release of its honey core. However, after the release of the core, the taste of the lozenge becomes unpleasant, too pronounced and strong in the mouth.

[0096] Overall, with more than 80% of “Agree” and “Completely agree” responses, the panelists declare that the melting heart lozenge according to example 1 (89%) and the Oropolis lozenge (82%) do not hurt the mouth when tasting.

[0097] Comparing the two lozenges, the Oropolis lozenge hurts the mouth significantly more than the melting heart lozenge according to example 1 when sucked.

[0098] According to the panelists' comments, the Oropolis lozenge is rougher in the mouth than the lozenge according to example 1 and therefore tends to irritate the tongue and palate more. In addition, some panelists explain that when the liquid core is released, the hard sugar that has not yet melted becomes slightly sharp.

[0099] Overall, the panelists agreed that they perceived a difference in texture when tasting, whether with the melting heart lozenge according to example 1 (83%) or the Oropolis liquid heart lozenge (68%).

[0100] The panelists explained that the texture of the lozenges changes in the mouth. They are, at first, hard in the mouth, then, as the hard sugar melts, become soft and a honeyed center appears.

[0101] 91% of the panel "Agree" to "Completely agree" that the lozenge according to example 1 releases a melting heart in the mouth during tasting.

[0102] 52% of the panel "Agree" to "Completely agree" that the lozenge Oropolis releases a liquid heart into the mouth during tasting.

[0103] The panelists are significantly more in agreement that the lozenge according to example 1 releases a melting honey core than that the Oropolis lozenge releases a liquid core.

[0104] The panelists explain that they perceive a slight coating effect mainly once the honey core has been released.

[0105] Comparing the 2 lozenges, the lozenge according to example 1 would still have a more covering effect than the Oropolis lozenge (significant difference).

[0106] Panelists rated the throat-lining effect of the lozenges before and after the release of their honey core.

[0107] Whether for the Oropolis lozenge or according to example 1, a little less than half of the panel perceived a coating effect in the throat before the release of the honey heart.

[0108] Concerning the lozenge according to example 1, after the release of the melting core, the percentage of panelists having perceived a coating effect increases significantly and goes from 45% to 60%.

[0109] The release of the honey core of the lozenge according to example 1 provides a more present coating effect in the throat than before its release.

[0110] Regarding the Oropolis lozenge, the release of the liquid core does not increase the perception of a coating effect in the throat. The percentage of panelists perceiving a coating effect is equivalent before and after release of the liquid core.

[0111] With averages ranging from around 7 to 8 out of 10, the panelists were generally satisfied with the 2 pastilles tasted.

[0112] With an average of approximately 8 out of 10, the melting heart lozenge according to example 1 is significantly more appreciated than the Oropolis lozenge (approximately 7 out of 10).

[0113] When the panelists were asked which lozenge they would choose between the lozenge according to example 1 and the Oropolis lozenge to soothe their throat in case of discomfort, almost 80% of the panel chose the melting heart lozenge according to example 1 against only 24% the Oropolis lozenge.

[0114] The panelists explained that the melting heart lozenge according to example 1 has a better taste in the mouth than the Oropolis lozenge. It is pleasant and smooth in the mouth, both in terms of its texture and its good honey taste. Regarding its perceived effectiveness in soothing the throat, once its melting honey heart is released, it provides a sensation of a coating effect in the throat that is a little more present than the Oropolis lozenge.

[0115] The Oropolis liquid heart lozenge has a taste that is too strong and persistent in the mouth (bitterness, spiciness, etc.), mainly after the honey heart is released.

Claims

Claims

1. Combination product comprising, as active ingredients, at least Manuka honey, eucalyptus and marshmallow in the form of a single composition in a physiologically acceptable medium comprising at least: - (i) 50 to 500 mg, preferably 100 to 400 mg of honey - (ii) 1 to 10 mg, preferably 2 to 5 mg of eucalyptus, preferably Eucalyptusglobulus - (iii) 5 to 200 mg, preferably 10 to 100 mg of marshmallow to help relieve the symptoms of sore throats

2. Combination product according to one of the preceding claims, characterized in that the physiologically acceptable medium is suitable for oral administration.

3. Combination product according to one of the preceding claims, characterized in that it is in the form of a lozenge.

4. Combination product according to one of the preceding claims, characterized in that it is in the form of a lozenge having a hard shell and a melting core.

5. Combination product according to one of the preceding claims, characterized in that the eucalyptus is in the form of essential oil.

6. Combination product according to one of the preceding claims, characterized in that the marshmallow is in the form of a plant extract.

7. Combination product according to one of the preceding claims, characterized in that it contains a sweetening agent chosen from glucose syrup, sucrose, glucose, fructose, invert sugar, honey, maltose, polyol, preferably glucose syrup and sucrose.

8. Combination product according to at least one of the preceding claims, for use in the treatment of sore throats.